Health Care • Precision Instruments
$17.93 ▼ -0.06
(-0.33%)
MKT CAP: $2.32B • VOL: 3.76M
52W L $7 52W H $20
NEO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $727.3M | $660.6M | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $314.3M | $290.1M | — |
| Gross Margin % | 43.2% | 43.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$115.9M | -$92.1M | -$107.7M |
| Operating Margin % | -15.9% | -13.9% | — |
| Net Income (GAAP) | -$108.0M | -$79.0M | -$88.0M |
| EBITDA (Normalized) | -$94.3M | -$59.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $5.2M | $7.0M | -$2.0M |
| Capital Expenditures (CapEx) | $27.0M | $41.1M | — |
| Free Cash Flow (FCF) | -$21.8M | -$34.0M | -$2.0M |
| FCF Margin % | -3.0% | -5.2% | — |
| Return on Invested Capital (ROIC %) | -9.0% | -8.3% | — |
| Cash & Short-Term Equivalents | $159.6M | $367.0M | — |
| Total Debt (Short + Long Term) | $341.9M | $340.3M | — |
| Total Stockholders' Equity | $836.6M | $902.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NEO.